Valuation : Phathom Pharmaceuticals, Inc.

Market Cap 749M 645M 607M 553M 1.03B 71.27B 1.04B 7.19B 2.78B 36.31B 2.81B 2.75B 115B P/E 2026 *
-12.1x
P/E 2027 * 12.7x
Enterprise Value 751M 647M 609M 555M 1.04B 71.51B 1.04B 7.22B 2.79B 36.43B 2.82B 2.76B 115B EV / Sales 2026 *
2.37x
EV / Sales 2027 * 1.36x
Free-Float
94.82%
Yield 2026 *
-
Yield 2027 * -
1 day-7.00%
1 week-5.18%
Current month-8.25%
1 month+2.45%
3 months-10.59%
6 months-20.97%
Current year-47.08%
1 week 8.75
Extreme 8.75
9.65
1 month 8.4
Extreme 8.4
9.74
Current year 8.21
Extreme 8.21
18.09
1 year 8.21
Extreme 8.21
18.31
3 years 2.21
Extreme 2.21
19.71
5 years 2.21
Extreme 2.21
36.09
10 years 2.21
Extreme 2.21
64.54
Manager TitleAgeSince
Chief Executive Officer 61 2025-03-31
Director of Finance/CFO 66 2025-10-05
Compliance Officer - 2025-05-31
Director TitleAgeSince
Chairman 66 2022-01-31
Director/Board Member 71 2019-09-26
Director/Board Member 54 2019-11-30
Date Insider Type Main position Quantity % Market Cap. Importance
7/14/26 Tax

Controller/Auditor

-1,555 0.0019%
5/22/26 Don

Director

-56,000 0.0702%
5/20/26 Exercice

Director

35,000 0.0439%
Change 5-day change 1-year change 3-year change Capi.($)
-7.05%-5.18%-31.89%-34.03% 749M
+0.11%-2.84%+50.17%+89.26% 1,002B
-0.73%-2.71%+51.31%+64.61% 649B
+0.17%-4.70%+18.53%+67.34% 440B
-0.80%-0.43%+28.92%+36.94% 346B
-0.13%-14.97%+9.41%+26.44% 263B
-1.90%-2.72%-2.72%+10.93% 250B
-0.47%-11.58%+39.85%+49.61% 213B
-1.06%-4.23%-14.70%-57.76% 201B
-0.67%-2.65%+25.82%+89.05% 182B
Average -1.22%-1.81%+17.47%+34.24% 354.44B
Weighted average by Cap. -0.41%-2.39%+32.07%+56.00%

Financials

2026 *2027 *
Net sales 317M 272M 256M 234M 437M 30.12B 439M 3.04B 1.17B 15.34B 1.19B 1.16B 48.61B 494M 425M 400M 365M 683M 47.03B 685M 4.75B 1.83B 23.96B 1.86B 1.82B 75.91B
Net income -64.28M -55.32M -52.09M -47.46M -88.8M -6.12B -89.15M -617M -239M -3.12B -241M -236M -9.87B 59.06M 50.82M 47.85M 43.6M 81.58M 5.62B 81.9M 567M 219M 2.86B 222M 217M 9.07B
Net Debt 2.43M 2.09M 1.97M 1.79M 3.35M 231M 3.37M 23.31M 9.01M 118M 9.11M 8.92M 373M -77.63M -66.8M -62.9M -57.31M -107M -7.39B -108M -745M -288M -3.76B -291M -285M -11.92B
Logo Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of novel treatments for gastrointestinal diseases. It has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) for the United States (U.S.), Europe and Canada. PCABs are a novel class of molecules that block acid secretion in the stomach. The Company markets vonoprazan in the U.S. as VOQUEZNA (vonoprazan) tablets for the relief of heartburn associated with non-erosive gastroesophageal reflux disease (Non-Erosive GERD) in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA DUAL PAK (vonoprazan tablets, amoxicillin capsules) and VOQUEZNA TRIPLE PAK (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) for the treatment of H. pylori infection in adults.
Employees
371
Date Price Change Volume
26-09-09 US$8.760 -7.10% 451,748
26-09-08 US$9.430 -0.74% 1,032,666
26-09-04 US$9.500 +4.97% 1,236,691
26-09-03 US$9.050 -2.27% 663,058
26-09-02 US$9.260 -1.38% 932,646
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
9.430USD
Average target price
21.50USD
Spread / Average Target
+128.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PHAT Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!